This 2023 study, published in International Immunopharmacology, investigates the potential of low-dose naltrexone (LDN) in treating post-acute sequelae of COVID-19 (PASC), commonly known as long COVID. The researchers explored LDN's immunomodulatory effects, particularly its ability to reduce neuroinflammation and modulate immune responses, which are believed to contribute to long COVID
